Qianhai Health Holdings Ltd.

Qianhai Health Holdings Ltd.

HHKEX:911
0.30
HKD
0.00
(0.00%)
48.29MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.35
27.76
16.71
2.51
1.16
0.46
3.47
4.49
1.67
11.58
5.67
3.07
4
- -
Basic EPS, GAAP
3.43
4.67
-8.77
-3.73
0.21
0.03
0.16
- -
-0.01
-1.38
-0.31
0.01
0.04
- -
Free Cash Flow per Basic Share
1.25
-14.7
-2.63
1.02
0.32
-0.35
-2.43
-0.42
-0.26
-0.03
0.01
0.02
0.23
- -
Dividend per Share
- -
2.28
4.4
- -
- -
0.1
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.84
21.78
10.14
3.65
3.91
3.75
3.91
3.98
3.96
2.58
2.27
2.28
2.31
2.28
Tangible Book Value per Share
4.84
21.78
10.14
3.65
3.34
3.75
3.91
3.98
3.96
2.58
2.27
2.28
2.31
2.28
Basic Weighted Avg Shares
38
44
50
141
170
170
169
169
169
169
169
169
169
169
Sales/Revenue/Turnover
763
1,220
836
354
197
78
588
761
283
1,962
961
520
677
- -
Operating Margin (%)
20.31
19.72
-36.73
-134.93
-10.07
-40.5
1.84
0.87
-5.67
-13.09
-5.32
-8.94
1.03
- -
Depreciation Expense
2
3
4
5
3
2
2
3
2
2
2
2
2
- -
Net Income, GAAP
129
205
-438
-526
36
5
27
-1
-1
-234
-53
1
6
- -
Effective Tax Rate (%)
15.91
11.01
- -
- -
0.16
- -
- -
- -
- -
- -
- -
- -
0.03
- -
Profit Margin (%)
16.86
16.84
-52.47
-148.34
18.2
6.5
4.54
-0.11
-0.31
-11.91
-5.48
0.25
0.88
- -
Working Capital
149
964
305
461
376
389
386
493
622
408
358
365
372
365
LT Debt
3
1
- -
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
Total Equity
242
1,089
510
620
673
636
662
673
671
437
384
386
391
386
Return on Invested Capital (%)
- -
12.54
- -
- -
7.97
- -
4.09
- -
- -
- -
- -
-12.05
1.46
- -
Return on Capital (%)
- -
12.92
- -
- -
5.49
- -
4.1
- -
- -
- -
- -
0.35
1.54
- -
Return on Common Equity (%)
- -
30.85
-54.92
-93.27
5.58
0.78
4.12
-0.12
-0.13
-42.21
-12.84
0.34
1.53
- -

Capital Structure

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
169
169
169
Market Capitalization
63
47
48

Working Capital

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
452
500
386
Cash, Cash Equivalents & STI
20
2
23
Accounts Receivable, Net
- -
- -
99
Inventories
330
375
189
Total Current Liabilities
94
125
21
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.51%
-9.09%
1.46%
Free Cash Flow
99.28%
192.14%
813.6%
Net Income, GAAP
2,655.26%
5,280.32%
353.17%
Sales/Revenue/Turnover
98.3%
92.56%
30.29%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
961
2024
- -
- -
520
2025
- -
- -
677

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.31
2024
- -
- -
0.01
2025
- -
- -
0.04

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Chee Lap Yuen
Full Time Employees
19
Sector
Distribution services
Industry
Medical distributors
Address
Leighton Centre Hong Kong Hong Kong
IPO Date
Jun 27, 2014
Business
Qianhai Health Holdings Limited (0911.HK), an investment holding company incorporated in the Cayman Islands in 2011 and listed on the Main Board of The Stock Exchange of Hong Kong in 2014, principally engages in the trading and sale of electronic component products and health-care products from its headquarters in Sheung Wan, Hong Kong. The company operates through two main segments, offering electronic components such as NAND flash wafers, embed multi-chip package memory, semiconductors, central processing units and general electronic components to customers in consumer electronics, automotive, industrial applications and information technology sectors; and health-care products including Chinese herbal medicines, American ginseng, ginseng wine, healthy drinks, skincare, body-care items and food supplements primarily to wholesalers and retailers in Hong Kong and the People's Republic of China. It maintains a subsidiary relationship with Explorer Rosy Limited and employs a multi-faceted procurement strategy combining back-to-back orders and strategic bulk purchases from branded upstream manufacturers. In recent developments, the company completed a ten-to-one share consolidation effective May 2024 and adopted a new share option scheme in June 2024; disposed of its entire interests in Huge Hope Holdings Limited and its subsidiary on November 28, 2024; reported revenue growth of 11% to HK$340.9 million for the first half of 2025 driven by electronic component sales amid AI, 5G and automotive demand, though gross profit declined due to pricing pressures; and continues negotiating potential investments in manufacturing facilities in the PRC for value-added services, food processing factories for health supplements, and authorised distributorships for health-related products while actively sourcing new offerings in the health-care segment.